2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Pediatric, Young Adult
PAPER

4886 Developmentally guided human iPSC-derived HSCs show consistent serial multilineage engraftment from healthy donor cells and partial hematopoietic rescue after FANCA correction

Huseyin Abdik, PhD, Taha Bartu Hayal, PhD2, Chuanfeng Wu3, jizhong Zou4, Jianyi Ding, PhD5, Daisuke Araki, MD6, Andre Larochelle, MD, PhD7
1 National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States
2 National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States
3 National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States
4 National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States
5 National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States
6 National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States
7 National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States

Fanconi anemia (FA), the most prevalent inherited bone marrow (BM) failure syndrome, causes progressive hematopoietic stem cell (HSC) depletion. Allogeneic transplantation is curative but carries the risk that graft-versus-host disease accelerates squamous cell carcinoma, and autologous gene therapy is constrained by a small, fragile HSC pool. HSCs generated from induced pluripotent stem cells (iPSCs) could provide a renewable, gene-correctable autologous graft. Developmentally guided protocols yield engrafting cells from healthy iPSC lines, but serial repopulation, cryopreservation compatibility and applicability to inherited BM failure remain incompletely established. We compared the in vitro hematopoietic differentiation and in vivo repopulating capacity of hematopoietic stem and progenitor cells (HSPCs) generated from healthy donor (HD)- and Fanconi anemia (FA)-derived iPSCs

We evaluated KOLF2.1J HD iPSCs and 3 lines from one patient with compound-heterozygous FANCA variants c.2957delA and c.2316G>C: fibroblast-derived uncorrected FA (FA-UC), T-cell-derived monoallelic-corrected FA (FA-MC; c.2957delA), and its biallelic-corrected derivative (FA-BC). The c.2957delA was corrected by HiFiCas9-gRNA RNP and ssODN before SeV reprogramming, followed by c.2316G>C correction in FA-MC iPSCs using the same approach. Cells were differentiated using a developmentally guided embryoid body protocol adapted from Ng et al. (Nat Biotechnol 2024). Differentiation was assessed by stage-resolved RT-qPCR, flow cytometry, and colony-forming unit (CFU) assays. Fresh KOLF2.1J and FA-MC products and cryopreserved KOLF2.1J products were transplanted retro-orbitally into busulfan-conditioned NBSGW mice (2.5 × 10⁶ cells/mouse); FA-BC transplants are ongoing. Human CD45⁺ chimerism was measured in peripheral blood (PB) at weeks 4, 8, 12, and 16 and in BM and spleen at week 16. CD20⁺ B-, CD3⁺ T-, and CD33⁺ myeloid output was quantified. Purified human CD45⁺ primary BM cells (4–10 × 10⁶ cells/mouse) were serially transplanted into secondary recipient mice.

KOLF2.1J differentiation recapitulated developmental hematopoiesis. BRACHYURY and MESP1 peaked at days 1-3 and KDR at day 5, consistent with mesodermal induction; progressive DLL4 and SOX17 induction marked arterial endothelial specification, followed by RUNX1 upregulation during endothelial-to-hematopoietic transition (EHT). By days 13-15, HSC-associated transcripts HLF, HOXA9, MECOM, MLLT3, and SPINK2 and maturation markers HLA-DR and MSI2 were induced versus undifferentiated iPSCs, yielding 6 CD34⁺ cells per input iPSC. CD43⁺CD45⁺CD34⁺ cells comprised >99% of day-15 hematopoietic cells. Within this gate, median CD45RA⁻CD90⁺ frequencies were 89.5% (range, 87.4-98.1; n=5) in HD, 43.6% (1.9-49.0; n=3) in FA-MC, 42.1% (1.0-83.2; n=2) in FA-BC, and 4.5% (1.3-10.4; n=5) in FA-UC. FANCA correction increased CFU output 24- to 26-fold, from 5±1 CFU/1,000 FA-UC cells to 130±4 in FA-MC and 120±3 in FA-BC, reaching 60%-65% of KOLF2.1J output (200±5; mean±SD).

All 15 primary recipients of KOLF2.1J-derived HSPCs engrafted durably. Median PB chimerism increased from 1.0% at week 4 to 7.5%, 41.2%, and 44.8% at weeks 8, 12, and 16, respectively (P<0.0001, Friedman). Terminal median chimerism was 95.1% (2.7-98.0) in BM and 76.4% (5.2-90.5) in spleen. All recipients showed multilineage reconstitution (BM medians: CD20, 41.7%; CD33, 21.0%; CD3, 9.7%) and a persistent CD34⁺CD38⁻ compartment (0.63% of human cells). BM was evaluable in 6 of 7 secondary recipients; all 6 engrafted at high levels (median, 20.2%; range, 16.2%-44.1%), with CD33-dominant output in 5 of 6. Cryopreserved KOLF2.1J products engrafted all 5 recipients with B-, T-, and myeloid output; median BM and spleen chimerism were 68.0% (0.4%-95%) and 62.0% (0.1%-71%), respectively. FA-MC products generated measurable human cells in BM and spleen of all 9 recipients; median chimerism was 0.32% in BM (0.10%-37.8%) and 0.50% in spleen (0.21%-1.48%), including one recipient with 37.8% BM chimerism.

Developmentally guided differentiation of KOLF2.1J iPSCs generated consistent long-term multilineage engraftment, serial repopulation, and cryopreservation-compatible engraftment, establishing a robust HD iPSC platform. The partial hematopoietic rescue observed in corrected FA lines suggests that significant barriers to HSC development persist despite genetic correction, warranting further mechanistic investigation and protocol optimization.

Huseyin Abdik, PhD: No relevant conflicts of interest to declare.